The following table presents the amounts of share-based compensation expense recognized in LivaNova’s condensed consolidated statements of income (loss) by type of arrangement (in thousands):


	Three Months Ended September 30,				Nine Months Ended September 30,
	2026		2025		2026		2025
Service-based RSUs	$	8,254	$	4,715	$	21,004	$	12,784
Service-based SARs	2,945		3,494		9,881		9,628
Market performance-based RSUs	1,276		629		3,532		1,558
Operating performance-based RSUs	1,721		748		4,121		2,030
Employee share purchase plan	359		361		1,169		904
	$	14,555	$	9,947	$	39,707	$	26,904

Share-based compensation granted for the nine months ended September 30, 2026, representing potential shares and their weighted average grant date fair values by type, is as follows (shares in thousands, fair value in dollars):


	Nine Months Ended September 30, 2026
	Shares	Weighted Average Grant Date Fair Value
Service-based RSUs	580	$	62.77
Performance-based RSUs (1) (2)	188	70.26

(1)Awards cliff vest after three years and are subject to performance conditions, including the rank of LivaNova’s total shareholder return for the three-year period ending December 31, 2028 relative to the total shareholder returns of the S&P Healthcare Equipment Select Constituents index, as well as the achievement of specified cumulative revenue growth and adjusted earnings per share performance thresholds.

(2)Represents shares based on an assumed 100% performance achievement. Performance-based RSU awards have a minimum and maximum possible achievement level of 0% and 200%, respectively.